Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease.
Hongpeng ShiTong XueYang YangChenyu JiangShixing HuangQi YangDong LeiZhengwei YouTuo JinFei WuQiang ZhaoXiaofeng YePublished in: Science advances (2020)
Cardiovascular disorders are still the primary cause of mortality worldwide. Although intramyocardial injection can effectively deliver agents to the myocardium, this approach is limited because of its restriction to needle-mediated injection and the minor retention of agents in the myocardium. Here, we engineered phase-transition microneedles (MNs) coated with adeno-associated virus (AAV) and achieved homogeneous distribution of AAV delivery. Bioluminescence imaging revealed the successful delivery and transfection of AAV-luciferase. AAV-green fluorescent protein-transfected cardiomyocytes were homogeneously distributed on postoperative day 28. AAV-vascular endothelial growth factor (VEGF)-loaded MNs improved heart function by enhancing VEGF expression, promoting functional angiogenesis, and activating the Akt signaling pathway. The results indicated the superiority of MNs over direct muscle injection. Consequently, MNs might emerge as a promising tool with great versatility for delivering various agents to treat ischemic myocardial disease.
Keyphrases
- vascular endothelial growth factor
- gene therapy
- signaling pathway
- ultrasound guided
- endothelial cells
- left ventricular
- poor prognosis
- pi k akt
- high resolution
- patients undergoing
- cell proliferation
- drug delivery
- binding protein
- cardiovascular events
- quantum dots
- single cell
- cancer therapy
- small molecule
- type diabetes
- living cells
- long non coding rna
- protein protein
- mass spectrometry
- energy transfer